Tracking Outcomes in Patients With Chronic Pain Prescribed Intravenous Lidocaine
Chronic Pain Syndrome
What this study involves
The registry says this study is recruiting. Individual locations may have different availability.
- Study type
- Observational
- Phase
- Not applicable / not listed
- Age range
- 18 years - 80 years
- Sex eligible
- All sexes
- Healthy volunteers
- Not reported
- Participants
- 100 Estimated
These are starting points, not an eligibility decision. The research team must review the full requirements.
About the research
The purpose of this research is to gather data on the performance and functionality of IV lidocaine infusions prescribed to patients with chronic pain.
Who may be able to participate?
The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.
Inclusion Criteria:
- Age 18-80 years
- Patients with chronic pain syndrome
- Patients that have been prescribed and scheduled to receive an intravenous lidocaine infusion treatment
Exclusion Criteria:
- Not willing to comply with the requirements of the study
Study population
Adult patients with chronic pain who are prescribed to receive an intravenous lidocaine infusion.
Understand screeningTreatment, groups and participation
The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.
- Assignment
- Not reported
- Masking
- Not reported
Patients with chronic pain who are prescribed to receive an intravenous lidocaine infusion.
Not reported in this registry record.
Drug: Lidocaine IV
Lidocaine IV DRUG
Intravenous (IV) infusion of lidocaine. Administered to adult patients with chronic pain.
What researchers are measuring
Outcome measures describe what is being studied. They are not proof that a treatment works.
Primary measures
Change from Baseline in Pain Intensity on the Visual Analog Scale (VAS) at 3 Months
Time frame: Baseline, 3 months post-infusion
Pain intensity is self-reported by the patient using the VAS to evaluate their level of pain relief. Scores range from 0 to 100, where 0 indicates no pain and 100 indicates the worst possible pain. A negative change score indicates
Secondary measures
Change from Baseline in Central Sensitization Index (CSI) at 3 Months
Time frame: Baseline, 3 months post-infusion
Evaluates changes in central sensitization symptoms. The CSI consists of 25 items scored from 0 to 4, with a total score ranging from 0 to 100. Higher scores indicate a higher degree of central sensitization.
Other measures
Patient-Reported Outcomes Measurement Information System (PROMIS)
Time frame: Baseline, 1 month post-infusion, 3 months post-infusion, 6 months post-infusion, and 12 months post-infusion
Evaluates patient-reported health status across multiple domains via the PROMIS-29.
Patient Global Impression of Change (PGIC)
Time frame: 1 month post-infusion, 3 months post-infusion, 6 months post-infusion, and 12 months post-infusion
Assesses patient-reported satisfaction and overall impression of change regarding their condition following the infusion.
Review the complete result tables and limitations in the official record.
Open official results ↗Research locations (1)
The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.
1 locations
International Spine Pain & Performance CenterWashington D.C., District of Columbia, United StatesRecruiting
Study team and timeline
- Lead sponsor
- International Spine, Pain and Performance Center
- Study start
- Nov 6, 2023 Actual
- Primary completion
- Dec 31, 2027 Estimated
- Study completion
- Dec 31, 2028 Estimated
- First posted
- Nov 10, 2026 Actual
- Last updated
- Nov 10, 2026 Actual
Official study contacts
Official study title
Tracking Outcomes by Secondary Diagnoses in Patients Prescribed Intravenous Lidocaine for Chronic Pain
Ask Wellness Clinical Research
Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.
Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.
Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026